8-K: Boundless Bio Stockholders Affirm Board and Auditor at Annual Meeting

Boundless Bio, Inc. announced that its stockholders elected two Class I directors and ratified KPMG LLP as its independent registered public accounting firm for 2025 at the annual meeting held on June 23, 2025.

Summary

• At the annual meeting of stockholders held on June 23, 2025, Boundless Bio, Inc. stockholders voted on two key proposals.
• Proposal 1 involved the election of two Class I director nominees: Christine Brennan, Ph.D., and Nancy Whiting, Pharm.D., both of whom were successfully elected to hold office until the Company's 2028 annual meeting.
• Christine Brennan received 9,252,440 votes For, 5,046,258 votes Withheld, and 3,540,518 Broker Non-Votes.
• Nancy Whiting received 9,758,214 votes For, 4,540,484 votes Withheld, and 3,540,518 Broker Non-Votes.
• Proposal 2 concerned the ratification of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, which was overwhelmingly approved.
• KPMG LLP's appointment was ratified with 17,791,309 votes For, 47,807 votes Against, and 100 Abstentions.

Sentiment

Score: 7

Explanation: The document reports the successful completion of routine corporate governance matters, including the election of directors and ratification of the independent auditor, indicating stable operational continuity and shareholder alignment on these procedural items.

Positives

• The successful election of both director nominees ensures continuity and stability in the company's governance.
• The overwhelming ratification of KPMG LLP as the independent auditor for 2025 demonstrates strong shareholder confidence in the company's financial oversight and reporting processes.

Future Outlook

The document does not contain specific forward-looking statements or financial guidance beyond the election of directors to serve until the 2028 annual meeting and the ratification of the auditor for the fiscal year ending December 31, 2025.

Industry Context

This filing represents a routine corporate governance update for a publicly traded biotechnology company, reflecting standard procedures for annual stockholder meetings, including director elections and auditor ratification. Such events are common across the industry and are essential for maintaining corporate transparency and accountability.

Corporate Governance

Stakeholder Impact

• Shareholders: The successful election of directors and ratification of the auditor demonstrate that shareholders have approved the company's proposed governance structure and financial oversight, providing clarity on leadership and accountability.
• Management: The results affirm management's proposals for board composition and auditor selection, allowing for continued focus on strategic objectives.

Next Steps

• The elected Class I directors, Christine Brennan, Ph.D., and Nancy Whiting, Pharm.D., will hold office until the Company's 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified.

Key Dates

Recommendation

Keywords

Boundless Bio, BOLD, SEC filing, 8-K, stockholder meeting, annual meeting, director election, KPMG, auditor ratification, corporate governance, biotechnology, pharmaceuticals